Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Receives $36.50 Consensus Price Target from Analysts

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) has received a consensus rating of “Hold” from the eight research firms that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a strong buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $36.50.

Several equities analysts have recently commented on LKFT shares. Zacks Research lowered shares of Lakefront Biotherapeutics American Depositary Shares from a “hold” rating to a “strong sell” rating in a research report on Friday, May 8th. Raymond James Financial restated a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, February 24th. Wall Street Zen lowered shares of Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings restated a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, May 26th. Finally, Royal Bank Of Canada upped their price target on shares of Lakefront Biotherapeutics American Depositary Shares from $32.00 to $33.00 and gave the stock a “sector perform” rating in a research report on Tuesday, February 24th.

Lakefront Biotherapeutics American Depositary Shares Price Performance

LKFT stock opened at $27.54 on Thursday. The firm has a fifty day moving average price of $28.60 and a two-hundred day moving average price of $31.33. The firm has a market cap of $1.81 billion, a price-to-earnings ratio of -19.53 and a beta of 0.25. Lakefront Biotherapeutics American Depositary Shares has a 1-year low of $26.42 and a 1-year high of $37.78.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last released its quarterly earnings results on Sunday, February 15th. The biotechnology company reported $13.92 EPS for the quarter. The firm had revenue of $1.06 billion for the quarter. As a group, analysts expect that Lakefront Biotherapeutics American Depositary Shares will post -6.32 EPS for the current fiscal year.

Hedge Funds Weigh In On Lakefront Biotherapeutics American Depositary Shares

Institutional investors and hedge funds have recently bought and sold shares of the stock. State of Wyoming bought a new position in Lakefront Biotherapeutics American Depositary Shares in the 2nd quarter valued at about $28,000. Van ECK Associates Corp grew its position in Lakefront Biotherapeutics American Depositary Shares by 61.6% in the 4th quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 750 shares in the last quarter. Arax Advisory Partners grew its position in Lakefront Biotherapeutics American Depositary Shares by 319.2% in the 4th quarter. Arax Advisory Partners now owns 2,335 shares of the biotechnology company’s stock valued at $76,000 after buying an additional 1,778 shares in the last quarter. Quadrant Capital Group LLC bought a new position in Lakefront Biotherapeutics American Depositary Shares in the 3rd quarter valued at about $134,000. Finally, Squarepoint Ops LLC bought a new position in Lakefront Biotherapeutics American Depositary Shares in the 3rd quarter valued at about $211,000. Institutional investors own 32.46% of the company’s stock.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.